Genevieve Desjardins | Principal Scientist in Protein Engineering
Zymeworks Inc | Canada

Genevieve Desjardins is a Principal Scientist and Group Lead in the Protein Engineering department at Zymeworks Inc, where she contributes to the discovery and development of next-generation multispecific antibody therapeutics. Her work in protein engineering has supported multiple clinical-stage programs, including Ziihera® (zanidatamab), a biparatopic HER2 targeted antibody, ZW171, a mesothelin targeted T cell engager, as well as ZW209, a DLL3-targeted T cell engager with CD28 co-stimulation. Her contribution spans from early discovery through IND filing with a focus on engineering robus therapeutic molecules with precise target engagement, optimized formats and excellent developability to tackle complex biological problems. Genevieve has over 10 years of industry experience working on antibody drug development, platform engineering and leading programs across oncology and immunology indications. Her contributions have helped drive innovative approaches to multispecific design, including optimization of format, affinity, stability, and manufacturability. She holds advanced training in the life sciences, including a Masters from the Université de Montréal and a PhD from the University of British Columbia, with a strong academic foundation in protein biochemistry and structural biology. Genevieve is passionate about translating cutting-edge protein engineering technologies into impactful medicines for patients and actively engages in scientific collaboration and knowledge sharing within the biotech community.